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Summary
The revolut ionary progress in molecular genet ics of hereditary cancer is pushing
the cl in ical  genet ics of cancer into an accelerated evelopment.  For a discussion of
the issues involved, i t  is important to clar i fy the vocabulary. Therefore, in chapter í
of  this thesis a l ist  of  def ini t ions i  given for f requent ly used not ions in the cl in ical
genetics of cancer. From the review presented in chapter 2 it is clear that many
types of cancer may be associated with a human cancer syndrome. To asses the
possible presence of one of these syndromes in a cancer pat ient and his or her
family,  the family history general ly piays a central  role.  Unfortunately,  the contr ibu-
t ion of the family history to the genet ic diagnosis is l imited by i ts inaccuracy. The
study reported in chapter 3 has looked at factors influencing family history accu-
racy. lts results may help in the interpretation of (as yet) unverified family histories
and, i f  there is no opportunity to ver i fy them al l ,  in deciding which parts of those
histories need to be verified.
Recognizing from family histor ies the clues that point to human cancer syndromes
is usually the basis for the cancer-related referral to a clinical genetics centre.
However,  recognizing these clues may not be easy and some physicians may be
better aware of the characteristics of the human cancer syndromes than others. In
order to improve the quality of care to families with hereditary cancer it is important
to (regional ly) distr ibute and update information on the human cancer syndromes,
criteria for referral, options for DNA analysis and preventive measures (e.9.
screening protocols).
Such actions need, however, to be monitored in order to see whether this transfer
of knowledge is successful. In chapter 4 we presented an analysis of the referral
from the hospitals and general  pract i t ioners in our region.
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We observed str ik ing di f ferences within both of these groups and wi l l  use the
results in a dialogue with al l  part ies involved to ident i fy the cause of these di f feren-
ces and to see whether there is any need to adjust our system of knowledge trans-
fer.  This transfer should not be a one-way process. The cl in ical  genet ic workload
has for an important part shifted in recent years from the traditional topics of conge-
ni tal  anomalies and mental  retardat ion to cancer.  Therefore, al though non-genet i-
c ists may need to learn more about genet ic aspects of cancer,  c l in ical  genetrcists
need to learn more about cancer in order to be equal partners in the discussion on
hereditary cancer topics.
One way to assist  in the recognit ion of hereditary cancer and in making a cl in ical
genet ic di f ferent ial  diagnosis in cancer pat ients and famil ies, is to present informa-
t ion on this subject in the format of interact ive software, as has been done for c l in i-
cal  cytogenet ics ( the Human Cytogenet ics Database by Schinzel) ,  dysmorphology
(the London Dysmorphology Database by Winter and Barai tser;  POSSUM by
Bankier) and some other groups of hereditary disorders We programmed the
Famil ial  Cancer Database (FACD), reported in chapter 5, for this purpose Only
t ime wi l l  te l l  how much help our programme offers in cl in ical  pract ice.
Two of the human cancer syndromes, mult ip le ndocrine neoplasia type 2A
(MEN2A) and hereditary non-polyposis colorectal  cancer (HNPCC)were studied
with respect o the disease spectrum and tumour r isk. Results are reported in
appendices l - lV. In the two MEN2A studies, pat ients with famil ia l  cutaneous l ichen
amvloidosis (CLA) and famil ia l  or rsolated Hirschsprung disease (HSCR), respec-
t ively,  were examined for mutat ions rn the RET gene (which is associated with
MEN2). The reason for this was that both disorders have also been reported to
occur in MEN2A pat ients.  We therefore quest ioned whether CLA and HSCR
patients without a MEN2A family history could carry MEN2A-associated RET
mutat ions and thus could have an increased cancer r isk.  Indeed, such mutat ions
were observed in HSCR pat ients.  Al though tumour r isks for these HSCR pat ients
are as yet di f f icul t  to estrmate, our study underl ines the fact that some pat ients with
disorders known to be associated with human cancer syndromes, may carry
mutant genes associated with an increased cancer r isk in the absence of a family
history f i t t ing those syndromes Physicians diagnosing and treat ing pat ients with
such disorders hould be aware of this phenomenon in the interest of  tumour ore-
vent ion .
Disease spectrum and tumour r isk in HNPCC were explored in the studies reported
in  append ices  l l l  and  lV .  The f i rs t  s tudy  used an  ep idemio log ica lapproach to  look
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included in the Nat ional HNPCC Registry maintained by the Netherlands
Foundation for the Detection of Hereditary Tumours and presents risk figures for
these tumours. Studies such as this one have the advantage of generat ing r isk
f igures, but cannot learn us much of the nature of tumours which occur only rarely
in a human cancer syndrome.
The second study demonstrates a totally different approach to study the disease
spectrum. Using molecular techniques, a single case of mal ignant f ibrous hist iocy-
toma (very rarely occurr ing in HNPCC) diagnosed in an HNPCC pat ient was tested
for molecular character ist ics of HNPCC. The results suggested that this tumour
had indeed developed as part  of  HNPCC in this pat ient.  Both types of study, each
with its own particular advantages and disadrrantages, are needed to further deli-
neate the disease spectrum of the human cancer syndromes.
Future Perspectives
Many quest ions relevant to the cl in ical  genet ics of cancer remain to be answered.
Some of these may be more readi ly answered than others. For example, i t  is
unl ikely that we wi l l  be able in the near future to precisely predict  he cl in ical  impl i -
cat ions of a mutant gene in individual cases. Inter- and intra-famil ia l  di f ferences in
phenotypical  expression of one and the same mutant gene are the rule rather than
the except ion in human.cancer syndromes and can be explained by the mult i -step
nature of cancer development and the fact that a wide range of external as wel l  as
internal risk and protective factors may interact in complex and therefore largely
unpredictable ways.
The fr-r ture wi l l ,  however,  undoubtedly see an expansion of diagnost ic apabi l i t ies.
In part icular,  we can expect DNA analysis to contr ibute increasingly to the genet ic
diagnosis in pat ients and famil ies uspected of having a human cancer syndrome.
Although increased mutation detection rates will generate a further increase in
demand for genetic services with all the practical budgetary problems tied in with
this increase, the possibi l i ty to detect ai l  mutat ions associated with human cancer
syndromes will also alleviate the burden of family history verification and the 'wrest-
l ing'  with di f ferent ial  diagnosis.
Quest ions with regard to tumour prevent ion in individuals and famil ies wi l l  probably
take many more years to solve, which impl ies that more people wi l l  be diagnosed
with an inheri ted strong cancer predisposit ion at a t ime when the value of preven-
t ive opt ions wi l l  st i l l  be very unclear for many of the human cancer syndromes as
reviewed in chapter 2. Only large col laborat ive studies can address quest ions with
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respect o outcome of per iodic screening, tumour incidence after prophylact ic
surgery and the short-  and long-range f fects and side-effects of chemoprevent ion.
This impl ies that the (prevent ive) treatment and fol low-up of pat ients hould be
protocol ized in order to be able to compare and pool data. This is a strong
argument in favour of central is ing these medical act iv i t ies. However,  in pract ice,
many of these activities are not performed in central settings.
Although genet ic analysis is of ten central ised per region because of the very spe-
cial ised expert ise involved (and because of legislat ion, as in our country),  depend-
ing cn the choice of inclusion cr i ter ia,  the load of pat ients for further medical
management may be too large to cope with in a central  c l in ic.  Also, pat ients may
prefer to remain in the care of special ists working outside such central  c l in ics. l f  de-
central ised medical management would fol low the mentroned protocols and i ts
local registrat ion could be carr ied out in a way that would al low for the pool ing of
data on regional and preferably nat ional levels so that a study populat ion could be
def ined large enough for meaningful  stat ist ical  nalysis,  then that could be an
adequate al ternat ive. Nevertheless, certain medical  procedures (e. g.  prophylact ic
thyroidectomy in smal l  chi ldren, presymptomatic DNA test ing including i ts psycho-
logical  support)  should remain central ised for the present in order to guarantee
expenrse
Looking at the future, i t  can hardly be expected that diagnost ic and even pre-
symptomatic DNA test ing and genet ic counsel l ing wi l l  forever emain the exclusive
domain of c l in ical  genet ics centres. Simply because of the sheer number of pa-
t ients involved and the opening of internat ional markets for commercial  DNA
test ing, decentral isat ion f  test ing and counsel l ing seems l ikely.  The role of c l in ical
genet ics centres may shif t  towards one which mainly focuses on hereditary dis-
orders which are part icular ly complex with regard to DNA test ing, r isk analysis and
counsel l ing, as wel l  as on disorders for which, because of their  rare nature, com-
mercial  test ing is unavai lable.
With respect o the other disorders, an increasing role as a consultancy service,
rather than as a service which performs al l  of  the actual test ing and counsel l ing,
may be expected. However,  these changes should not be encouraged unt i l
comprehensive mutat ion analysis wi l l  be possible and the cl in ical  and psychosocial
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